In a patient with systemic lupus erythematosus, what is the significance of leukocytosis and how should it be evaluated and managed?

Leukocytosis in SLE: Infection Until Proven Otherwise

In a patient with SLE presenting with leukocytosis, you must aggressively rule out infection first, as this represents the most immediate threat to mortality. Leukocytosis is distinctly unusual in SLE—the disease typically causes leukopenia, not leukocytosis—making an elevated white blood cell count a red flag for superimposed infection or other serious complications 1.

Clinical Significance and Immediate Evaluation

Why Leukocytosis Matters in SLE

SLE patients characteristically develop leukopenia and lymphopenia, not leukocytosis. The EULAR monitoring guidelines specifically emphasize tracking severe neutropenia (<500 cells/mm³) and severe lymphopenia (<500 cells/mm³) as markers of infection risk 1. When you see leukocytosis instead, this represents a departure from the expected pattern and demands urgent investigation.

Primary Differential Diagnosis

Infection is the leading concern when encountering leukocytosis in SLE patients because:

• SLE patients are inherently immunosuppressed from both disease and treatment
• Immunosuppressive medications (glucocorticoids, cyclophosphamide, mycophenolate) dramatically increase infection risk
• Infections are a major cause of morbidity and mortality in SLE 1, 2

Glucocorticoid effect is the second consideration:

• High-dose corticosteroids commonly cause leukocytosis through demargination of neutrophils
• This is a pharmacologic effect, not necessarily pathologic
• However, you cannot assume glucocorticoid effect without excluding infection

Other critical considerations:

• Hemophagocytic lymphohistiocytosis (HLH)/Macrophage Activation Syndrome—a life-threatening complication that can present with variable white counts, fever, cytopenias, hyperferritinemia, and hypertriglyceridemia 3, 4
• Active lupus flare (though this more commonly causes leukopenia)
• Medication reactions
• Underlying malignancy (SLE patients have increased lymphoma risk) 2

Evaluation Algorithm

Step 1: Assess for Infection Immediately

Obtain focused history for:

• Fever, chills, night sweats
• Localizing symptoms (cough, dysuria, abdominal pain, headache, skin lesions)
• Recent procedures or hospitalizations
• Current immunosuppressive regimen and doses

Physical examination targeting:

• Vital signs (fever, tachycardia, hypotension suggesting sepsis)
• Pulmonary examination (pneumonia)
• Skin examination (cellulitis, abscess)
• Neurologic examination (meningitis, encephalitis)

Immediate laboratory workup:

• Complete blood count with differential (assess for left shift, toxic granulation)
• C-reactive protein—critical in SLE: CRP is typically normal or minimally elevated in active lupus alone; CRP >50 mg/L strongly suggests bacterial infection rather than lupus activity 1
• Blood cultures before antibiotics
• Urinalysis and urine culture
• Chest radiograph

Pathogen-specific screening based on risk:

• CMV antigenemia if on high-dose glucocorticoids or pulse cyclophosphamide 1
• Tuberculosis evaluation if endemic area or before intensifying immunosuppression 1
• HIV, hepatitis B/C based on risk factors 1

Step 2: Review Medication History

Document:

• Current glucocorticoid dose and recent changes
• Timing of leukocytosis relative to steroid administration
• Other immunosuppressive agents (cyclophosphamide, mycophenolate, azathioprine, methotrexate)

Step 3: Evaluate for HLH/Macrophage Activation Syndrome

If patient has fever, cytopenias (despite leukocytosis, may have anemia/thrombocytopenia), and systemic inflammation:

Check HLH-2004 criteria markers:

• Ferritin (typically >500 ng/mL, often >10,000 ng/mL)
• Triglycerides (>265 mg/dL)
• Fibrinogen (<150 mg/dL)
• Soluble IL-2 receptor if available
• Bone marrow biopsy showing hemophagocytosis 3, 4

This is a medical emergency requiring immediate immunosuppression.

Step 4: Assess Lupus Disease Activity

Only after excluding infection:

• Anti-dsDNA and complement levels (C3, C4)—though these have limited predictive value 2
• Urinalysis for active sediment, proteinuria
• Clinical assessment of organ involvement

Important caveat: Active SLE typically causes leukopenia, not leukocytosis. If lupus activity is driving the presentation, you would expect low white counts, not high 1, 5, 6.

Management Approach

If Infection is Identified or Suspected

• Start empiric broad-spectrum antibiotics immediately if sepsis is suspected—do not delay for culture results
• Consider reducing or holding immunosuppressive agents (except glucocorticoids, which should be tapered cautiously)
• Maintain stress-dose steroids if patient is on chronic glucocorticoids
• Aggressive source control (drainage of abscesses, removal of infected lines)

If Glucocorticoid-Induced Leukocytosis

• No specific intervention needed if patient is clinically well
• Continue infection surveillance
• Work toward glucocorticoid minimization per EULAR guidelines: target <7.5 mg/day prednisone equivalent, with goal of discontinuation 7
• Add steroid-sparing immunosuppressive agents (azathioprine, mycophenolate, methotrexate) to facilitate taper 7, 2

If HLH/Macrophage Activation Syndrome

• Immediate high-dose corticosteroids (methylprednisolone 1000 mg IV daily for 3 days)
• Add IVIG and consider rituximab for refractory cases 4
• ICU-level monitoring
• Hematology consultation

Common Pitfalls to Avoid

1. Assuming leukocytosis is "just the steroids" without excluding infection—this can be fatal
2. Attributing leukocytosis to lupus flare—active lupus causes leukopenia, not leukocytosis
3. Delaying antibiotics while completing diagnostic workup in a septic-appearing patient
4. Missing HLH/MAS by not checking ferritin and triglycerides in febrile patients with cytopenias
5. Stopping glucocorticoids abruptly in chronically treated patients—risk of adrenal crisis

Monitoring After Resolution

Once the acute issue resolves, return to standard SLE monitoring per EULAR guidelines 1:

• Complete blood count at regular intervals
• Heightened surveillance for severe neutropenia (<500 cells/mm³) and lymphopenia (<500 cells/mm³) as infection risk markers
• Immunoglobulin levels if recurrent infections (IgG <500 mg/dL increases infection risk)
• Vaccination with inactivated vaccines (influenza, pneumococcus) when disease is inactive

The bottom line: Leukocytosis in SLE is abnormal and demands immediate evaluation for life-threatening infection, with CRP serving as a critical discriminator between infection (high CRP) and lupus activity (normal/low CRP).